HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

11a-N-tosyl-5-deoxi-pterocarpan

structure in first source

Also Known As:

LQB-223

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Buarque, Camilla Djenne: 2 articles (10/2019 - 10/2016)
2.	Lemos, Lauana Greicy Tonon: 2 articles (10/2019 - 10/2016)
3.	Maia, Raquel Ciuvalschi: 2 articles (10/2019 - 10/2016)
4.	Nestal de Moraes, Gabriela: 2 articles (10/2019 - 10/2016)
5.	Brum, Mariana Concentino Menezes: 1 article (10/2019)
6.	Cirilo, Caíque de Assis: 1 article (10/2019)
7.	Costa, Paulo Roberto Ribeiro: 1 article (10/2019)
8.	Gimba, Etel Rodrigues Pereira: 1 article (10/2019)
9.	Longo, Gabriel Mello da Cunha: 1 article (10/2019)
10.	Mendonça, Bruna Dos Santos: 1 article (10/2019)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 10/12/2019 - "Our data demonstrate that LQB-223 impairs 3D culture growth and migration in 2D and 3D models of breast cancer exhibiting different phenotypes." 10/12/2019 - "Here, we investigated the mechanisms underlying LQB-223 antitumor effects in 2D and 3D models of breast cancer. " 10/01/2016 - "Together, these results show that LQB-223 mediates cytotoxic effects in sensitive and resistant breast cancer cells, while presenting low toxicity to non-neoplastic cells. " 10/01/2016 - "The LQB-223 decreased cell viability, inhibited colony formation and induced an expressive G2/M arrest in breast cancer cells. " 10/12/2019 - "Our results show that LQB-223, but not doxorubicin treatment, suppressed the migratory and motility capacity of breast cancer cells. "
2.	Leukemia 05/06/2014 - "11a-N-Tosyl-5-deoxi-pterocarpan (LQB-223), a promising prototype for targeting MDR leukemia cell lines."

Related Drugs and Biologics

1.	11a-N-tosyl-5-deoxi-pterocarpan
2.	Proteins (Proteins, Gene)
3.	Doxorubicin (Adriamycin)
4.	Antineoplastic Agents (Antineoplastics)